Center for Molecular Medicine
In order to promote cancer and translational research, the Center for Molecular Medicine (CMM) was established in June 2006.
Through translating basic research into clinical research, the CMM is dedicated to developing effective strategies for cancer prevention and treatment and to improve the well-being of cancer patients. There are currently 9 faculty members in the CMM, which is led by Dr. Hung (洪明奇), and all of them are specialized in cancer biology and cell signaling pathways. Our translational research is focused on the development of novel cancer treatments in Taiwan. In particular, the liver and lung gene therapies have been found to show excellent efficacies in animal models. The CMM has actively expedited these therapies to clinical trials.
Our basic research mainly investigates the signaling pathways of cancer and stem cells to discover novel biomarkers for diagnosing tumors and novel anti-cancer drug targets in order to expedite early diagnosis of cancer and the development of new anti-cancer drugs. These areas will definitely accelerate the development of targeted therapy and personalized medicine.
In addition to conducting research, CMM faculty members are responsible for teaching at the Graduate Institute of Cancer Biology (GICB) at China Medical University. The GICB opened for admission in the 2007 academic year, providing many relevant courses for fostering young scientists towards specializing in cancer research.
In addition to our collaboration with Dr. Hung’s laboratory at the University of Texas MD Anderson Cancer Center, we will also actively form domestic and international collaborations and obtain national research grants in order to enhance our competitiveness in research and to nurture future scientists.
The CMM aims to play a leading role in research on cell signaling and cancer biology in Asia.